Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: A preliminary study

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 2, 2004, Pages 337-343

  Janowsky, David S ^a   Davis, John M ^b   Overstreet, David H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acetylcholine; Cholinesterase inhibitors; DFP; Diarrhea; Diisopropyl fluorophosphate; Donepezil; Flinders rats; Hypoactivity; Hypothermia; Sarin; Scopolamine; Soman

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; DYFLOS; LONG ACTING DRUG; SCOPOLAMINE;

ADULTHOOD; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; EVALUATION; HYPOKINESIA; HYPOTHERMIA; MALE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; TEMPERATURE; TIME; TOXICITY;

ANIMALIA;

EID: 1642493734     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.11.012     Document Type: Conference Paper

References (53)

1. Anderson D.R., Harris L.W., Lennox W.J., Solana R.P. Effects of subacute pretreatment with carbamate together with adjunct pretreatment against nerve agent exposure. Drug Chem. Toxicol. 14(1-2):1991;1-19.
2. Anderson D.R., Gennings C., Carter W.H., Harris L.W., Lennox W.J., Bowersox S.L.et al. Efficacy comparison of scopolamine and diazepam against soman-induced debilitation in guinea pigs. Fundam. Appl. Toxicol. 22(4):1994;588-593.
3. Brown T.M., Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications: recognition and management. 1998;44-51 American Psychiatric Press, Washington (DC).
4. Clegg A., Bryant J., Nicholson T., McIntyre L., De Broe S., Gerard K.et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease. A systematic review. Int. J. Technol. Assess Health Care. 18:2002;497-507.
5. Coelho F., Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2:2001;CD001499.
6. Daws L.C., Overstreet D.H. Ontogeny of muscarinic cholinergic supersensitivity in the Flinders sensitive line rat. Pharmacol. Biochem. Behav. 62:1999;367-380.
7. Deshponde S.S., Viana G.G., Kauffman F.C., Rickett D.L., Albuquerque E.X. Effectiveness of physostigmine as a pretreatment drug for protection of rats from organophosphate poisoning. Fundam. Appl. Toxicol. 6:1986;566-577.
8. Dirnhuber P., French M.C., Green D.M., Leadbeater L., Stratton J.A. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J. Pharm. Pharmacol. 31:1979;295-299.
9. French M.C., Wetherell J.R., White P.D. The reversal by pyridostigmine of neuromuscular block produced by soman. J. Pharm. Pharmacol. 31:1979;290-294.
10. Harris L.W., Talbot B.G., Lennox W.J., Anderson D.R., Solana R.P. Physostigmine (alone and together with adjunct) pretreatment against soman, sarin, tabun and VX intoxication. Drug Chem. Toxicol. 14:1991;265-281.
11. Heath D.F. Organophosphorus poisons. 1961;Pergamon, New York.
12. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. 127S:2002;45-63.
13. Janowsky D.S. Central anticholinergics to treat nerve agent poisoning. Lancet. 359(9302):2002;265-266.
14. Janowsky, D.S., Overstreet, D.H. Pretreatment with donepezil protects against the hypothermic effects of the organophosphate, DFP. Program No. 205.4. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience; 2002.
15. Janowsky D.S., Berkowitz A., Turken A., Risch S.C. Antagonism of physostigmine induced lethality by a combination of scopolamine and methscopolamine. Acta Pharm. Toxicol. 56:1985;154-157.
16. Janowsky D.S., Risch D.S., Berkowitz A., Turken A., Drennan M. Central versus peripheral antagonism of cholinesterase inhibitor induced lethality. Hanin I. Dynamics of cholinergic function. 1986;791-798 Plenum Publishing, New York.
17. Janowsky D., Risch S.C., Ziegler M., Gillin J.C. Antagonistic effects of scopolamine and atropine on the physostigmine response in man. Mil. Med. 152:1987;579-581.
18. Keeler J.F., Hurst G.G., Dunn A.L. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA. 266:1991;693-695.
19. Lallement G., Baubichon D., Clarencon D., Galnnier M., Peoc'h M., Carpentier P. Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military and terrorist attack by soman. Neurotoxicology. 20:1999;675-684.
20. Lallement G., Foquin A., Dorandeu F., Baubichon D., Carpentier P. Subchronic administration of various pretreatments of nerve gas poisoning: II. Compared efficacy against soman toxicity. Drug Chem. Toxicol. 24:2001;165-180.
21. Lallement G., Demoncheoux J.P., Foquin A., Baubichon D., Galonnier M., Clarencon D.et al. Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity. Drug Chem. Toxicol. 25:2002;309-320.
22. Lallement G., Baille V., Bauibichon D., Carpentier P., Collombet J.M., Filliat P.et al. Review of the value of huperzine as pretreatment or organophosphate poisoning. Neurotoxicology. 23:2002;1-5.
23. Leadbeater L., Inns R.H., Rylands J.M. Treatment of poisoning by soman. Fundam. Appl. Toxicol. 5:1985;S225-S231.
24. Lennox W.J., Harris L.W., Anderson D.R., Solana R.P., Murrow M.I., Wade J.V. Successful pretreatment/therapy against soman, sarin, tabun and VX intoxication. Drug Chem. Toxicol. 15:1992;271-283.
25. Lim D.K., Ito Y., Yu H.J., Hoskins B., Ho I.K. Prevention of soman toxicity after the continuous administration of physostigmine. Pharmacol. Biochem. Behav. 31(3):1988;633-639.
26. Lim D.K., Hoskins B., Ho I.K. Trihexyphenidyl enhances physostigmine prophylaxis against poisoning in guinea pigs. Fundam. Appl. Toxicol. 16:1991;482-489.
27. Lynch M.R., Rice M.A., Robinson S.E. Dissociation of locomotor depression and ChE activity after DFP, soman and sarin. Pharmacol. Biochem. Behav. 24:1986;941-947.
28. McDonough J.H., McLeod C.G., Nipwoda M.T. Direct microinjection of soman or VX into the amygdala produces repetitive limbic convulsions and neurophathology. Brain Res. 435:1987;123-137.
29. Meshulam Y., Davidovici R., Wengier A., Levy A. Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs. J. Appl. Toxicol. 15:1995;263-266.
30. Miller S.A., Blick D.W., Kerenyi S.Z., Murphy M.R. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol. Biochem. Behav. 44(2):1993;343-347.
31. Morris J.C., Cyrus P.A., Orazem J., Mas J., Bieber F., Rusicka B.B.et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 50:1998;1222-1230.
32. Muggleton A.C., Bowditch A.F., Crofts H.S., Scott E.A.M., Pearce P.C. Assessment of a combination of physostigmine and scopolamine as pretreatment against the behavioural effects of organophosphates in the common marmoset (Callithrix jacchus). Psychopharmacology. 166:2003;212-220.
33. Overstreet D.H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci. Biobehav. Rev. 17:1993;51-68.
34. Overstreet D.H., Russell R.W., Helps S.C., Messenger M. Selective breeding for sensitivity to the anticholinesterase, DFP. Psychopharmacology. 65:1979;15-20.
35. Overstreet D.H., Russell R.W., Crocker A.D., Schiller G.D. Selective breeding for differences in cholinergic function: pre- and post-synaptic mechanisms involved in sensitivity to the anticholinesterase, DFP. Brain Res. 294:1984;327-332.
36. Overstreet D.H., Miller C.M., Janowsky D.S., Russell R.W. A potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Toxicology. 111:1996;119-134.
37. Philippens I.H., Melchers B.P., Olivier B., Bruijnzeel P.L. Scopolamine augments the efficacy of physostigmine against soman poisoning in guinea pigs. Pharmacol. Biochem. Behav. 65:2000;175-182.
38. Pratt R.D., Perdomo C.A., Surick I.W., Ieni J.R. Donepezil: tolerability and safety in Alzheimer's disease. Int. J. Clin. Pract. 56:2002;710-717.
39. Rezvani A.H., Overstreet D.H., Ejantkar A., Gordon C.J. Autonomic and behavioral responses of selectively bred hypercholinergic rats to oxotremorine and diisopropyl fluorophosphate. Pharmacol. Biochem. Behav. 48:1994;703-707.
40. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioral symptoms of dementia. Int. J. Clin. Pract. 127S:2002;20-36.
41. Russell R.W., Overstreet D.H., Messenger M., Helps S.C. Selective breeding for sensitivity to DFP. Generalization of effects beyond criterion variables. Pharmacol. Biochem. Behav. l7:1982;885-891.
42. Sipos M.L., Burchnell V., Galbicka G. Dose-response curves and time-course effects of selected anticholinergics on locomotor activity in rats. Psychopharmacology. 147:1999;250-256.
43. Sivam S.P., Hoskins B., Ho I.K. An assessment of comparative acute toxicity of diisopropyl-fluorophosphate, tabun, sarin, and soman in relation to cholinergic and GABAergic enzyme activities in rats. Fundam. Appl. Toxicol. 4:1984;531-538.
44. Solana R.P., Gennings D., Carter W.H.J., Anderson D., Lennox W.J., Carchman R.A.et al. Evaluation of the efficacy of two carbamates, physostigmine and pyridostigmine, when used in conjunction for protection against organophosphate exposure. Fundam. Appl. Toxicol. 15:1990;814-819.
45. Solberg Y., Belkin M. The role of excitotoxicity in organophosphorous nerve agents central poisoning. TIPS. 18:1997;183-185.
46. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H.et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306:2003;772-777.
47. Taylor P. Anticholinesterase agents. Hardman J.G., Limbird L.E., Molinoff P.B., Luddon R.W., Gilman A.G. The pharmacological basis of therapeutics. 1996;131-149 McGraw-Hill, New York.
48. Volans A.P. Sarin: guidelines on the management of victims of a nerve gas attack. J. Accid. Emerg. Med. 13:1996;202-206.
49. Von Bredow J., Corcoran K., Maitland G., Kaminskis A., Adams N., Wade J. Efficacy evaluation of physostigmine and anticholinergic adjuncts as a pretreatment for nerve agent intoxication. Fundam. Appl. Toxicol. 17:1991;782-789.
50. Walday P., Aas P., Haider T., Fonnum F. Effect of pyridostigmine pretreatment, HI-6 and toxogonin treatment on rat tracheal smooth muscle response to cholinergic stimulation after organophosphorus inhalation exposure. Arch. Toxicol. 67:1993;212-219.
51. Wetherell J.R. Continuous administration of low dose rates of physostigmine and hyoscine in guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J. Pharm. Pharmacol. 46:1994;1023-1028.
52. Wolfson C., Oremus M., Shukla V., Momoli F., Demers L., Perrault A.et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on the efficacy and cost-effectiveness. Clin. Ther. 24:2002;862-886.
53. Xia D.Y., Wang L.X., Pei S.Q. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against soman poisoning in vivo. Fundam. Appl. Toxicol. 1:1981;217-221.